{"id":"NCT01625377","sponsor":"Novartis Pharmaceuticals","briefTitle":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","officialTitle":"A National, Multi-center, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Everolimus Combined With Enteric-coated Mycophenolate Sodium Compared to the Standard Treatment Combining Tacrolimus and Enteric-coated Mycophenolate Sodium in de Novo Liver Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-06-21","resultsPosted":"2016-04-27","lastUpdate":"2016-04-27"},"enrollment":188,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Transplantation"],"interventions":[{"type":"DRUG","name":"tacrolimus","otherNames":["Prograf速"]},{"type":"DRUG","name":"everolimus","otherNames":["Certican速 / RAD001"]},{"type":"DRUG","name":"Basiliximab","otherNames":["Simulect速"]},{"type":"DRUG","name":"Mycophenolic Acid","otherNames":["Myfortic速"]},{"type":"DRUG","name":"Corticosteroids","otherNames":[]}],"arms":[{"label":"Tacrolimus","type":"ACTIVE_COMPARATOR"},{"label":"Everolimus (RAD001)","type":"EXPERIMENTAL"}],"summary":"The aims of the study was to evaluate the safety and efficacy of early introduction one month post-transplantation of everolimus associated to EC-MPS with tacrolimus discontinuation in de novo liver transplant recipients and to evaluate if it leads to a better renal function 6 month post-transplantation compared to standard treatment associating tacrolimus and EC-MPS.\n\nThe renal function was estimated by glomerular filtration rate.","primaryOutcome":{"measure":"Change From Baseline (Randomization) in Renal Function","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Tacrolimus","deltaMin":-13.29,"sd":2.75},{"arm":"Everolimus (RAD001)","deltaMin":1.05,"sd":2.81}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":14,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":94},"commonTop":["Cholestasis","Neutropenia","Diarrhoea","Hepatocellular injury","Anaemia"]}}